XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (64,005,625) $ (66,699,593)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,768,096 1,779,999
Amortization of intangible assets 983,021 1,214,602
Change in value of common stock warrants (360,795) (227,273)
Stock-based compensation 8,516,349 10,393,812
Amortization of premiums on investments 71,707 225,658
Loss on short-term investments 557,875 77,889
Deferred rent (277,892) 2,254,122
Loss (gain) on equity investment in affiliated entities (1,305,174) 7,275,462
Changes in operating assets and liabilities:    
Accounts receivable 3,171,498 9,584,433
Accounts receivable from affiliated entities (1,081,016) (176,322)
Prepaid expenses and other current assets 999,047 (2,789,784)
Prepaid expenses and other current assets from affiliated entities (261,187) 515,211
Other assets 13,695 (84,035)
Accounts payable and accrued expenses (4,888,115) 1,119,751
Accrued clinical trial expenses (1,258,837) 1,551,656
Accounts payable and accrued expenses due to affiliated entities (236,023) (289,701)
Deferred revenue (1,006,745) (14,736,401)
Deferred revenue from affiliated entities (105,685) (250,000)
Deferred grant funding 1,297,416 0
Deferred grant funding from affiliated entities 39,583 0
Other liabilities 99,669 0
Net cash used in operating activities (56,269,138) (49,260,514)
Cash flows from investing activities:    
Purchases of short-term investments (47,869,250) (82,268,656)
Proceeds from short-term investments 84,848,556 49,272,077
Purchases of capital assets (1,741,955) (9,415,836)
Net cash provided by (used in) investing activities 35,237,351 (42,412,415)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 14,923,263 94,347,922
Proceeds from stock option and warrant exercises, net of tax payments 1,719,767 1,466,927
Net cash provided by financing activities 16,643,030 95,814,849
(Decrease) Increase in cash and cash equivalents (4,388,757) 4,141,920
Cash and cash equivalents, beginning of period 23,786,579 19,136,472
Cash and cash equivalents, end of period 19,397,822 23,278,392
Supplemental disclosure of non-cash activities    
Change in amounts accrued for purchases of property and equipment $ 1,065,864 $ 1,809,948